Omneity® Pellets
All-In-One Vitamin & Mineral Pellet
Inhibition of interleukin-1 receptor-associated kinase (IRAK)-4 provides partial rescue of interleukin-1 beta induced functional and gene expression changes in equine tenocytes.
Abstract: Interleukin 1 beta (IL-1β) is upregulated following a tendon injury and in vitro studies have shown that it leads to numerous negative effects on tendon cell function and gene expression. IL-1β activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and we hypothesised that inhibiting NF-κB activation would mediate the negative effects of IL-1β on equine tendon cells in 3-dimensional (3D) cultures. Results: Here, we tested three inhibitors of NF-κB signalling (Bortezomib, BAY11-7082 and Wedelolactone) along withTJ-M2010-5, an inhibitor of MyD88, which is a critical adaptor protein for mediating IL-1β signalling. None of these inhibitors were able to rescue gel contraction by equine tenocytes exposed to IL-1β in 3D culture. However, the daily application of the interleukin-1 receptor-associated kinase (IRAK)-4 inhibitor PF-06650833 resulted in a partial rescue of collagen contraction and interleukin-6 (IL-6) production by equine tenocytes in 3D culture. Global gene expression using RNA sequencing also revealed a partial rescue, although this was not as complete as that achieved using interleukin-1 receptor antagonist protein (IL1Ra), with many inflammatory pathways remaining upregulated. ENPP2 expression was significantly increased by IL-1β and rescued by both IL1Ra and PF-06650833 suggesting ENPP2 may be involved in collagen contraction. However, direct ENPP2 inhibition does not rescue IL-1β mediated inhibition of contraction and ENPP2 inhibition alone reduces collagen contraction. Conclusions: Together, this data demonstrates that IL-1β has a broad mechanism of action on tendon cells which cannot be fully mediated by targeting specific parts of the signalling pathway.
© 2025. The Author(s).
Publication Date: 2025-11-06 PubMed ID: 41196436PubMed Central: PMC12592280DOI: 10.1007/s11033-025-11219-2Google Scholar: Lookup The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
Overview
- This study investigates how inhibiting specific components of the interleukin-1 beta (IL-1β) signaling pathway affects the negative impacts of IL-1β on equine tendon cells, particularly focusing on cellular function and gene expression changes in three-dimensional (3D) cultures.
- The research found that blocking interleukin-1 receptor-associated kinase 4 (IRAK-4) partially alleviates IL-1β-induced dysfunction and gene expression changes in these tendon cells, though not completely.
Background
- IL-1β is a pro-inflammatory cytokine upregulated after tendon injury and is known to disrupt normal tendon cell function and gene expression.
- IL-1β signals through pathways involving nuclear factor kappa B (NF-κB), leading to inflammation and reduced tendon healing capacity.
- The MyD88 adaptor protein and IRAK-4 kinase are key components in transmitting IL-1β signals inside cells.
- Strategies targeting these signaling molecules may help in counteracting IL-1β-induced damage in tendon cells.
Study Objectives
- To test whether inhibition of NF-κB activation or upstream signaling components could reverse IL-1β’s negative effects on equine tenocytes (tendon cells) in a 3D culture model.
- To evaluate the effects of different pharmacological inhibitors on cell function (gel contraction) and gene expression changes induced by IL-1β.
Methods
- Equine tenocytes were cultured in 3D collagen gels treated with IL-1β to mimic post-injury inflammatory conditions.
- Multiple inhibitors were tested:
- Bortezomib, BAY11-7082, and Wedelolactone: inhibitors acting downstream on NF-κB signaling.
- TJ-M2010-5: an inhibitor of MyD88, an adaptor protein directly involved in IL-1β signaling.
- PF-06650833: a specific inhibitor of IRAK-4 kinase.
- Interleukin-1 receptor antagonist protein (IL1Ra) was used as a reference control to block IL-1β receptor activation.
- Cell function was measured through contraction of the collagen gels, a process related to tendon healing.
- IL-6 production, a marker of inflammation, was also assessed.
- Gene expression changes were analyzed using RNA sequencing (RNA-seq) to understand global effects of IL-1β and the inhibitors.
- Expression and role of the gene ENPP2 were specifically studied, given its regulation by IL-1β and potential involvement in cell contraction.
Key Findings
- None of the NF-κB inhibitors (Bortezomib, BAY11-7082, Wedelolactone) nor the MyD88 inhibitor (TJ-M2010-5) were able to restore normal collagen gel contraction in the presence of IL-1β.
- The IRAK-4 inhibitor PF-06650833 partially rescued the ability of tenocytes to contract collagen gels and partially reduced IL-6 production.
- RNA sequencing showed that PF-06650833 partially reversed IL-1β-induced gene expression changes, but this rescue was incomplete compared to IL1Ra which had a broader inhibitory effect on inflammatory pathways.
- The gene ENPP2 was strongly upregulated by IL-1β and this increase was reversed by both IL1Ra and PF-06650833.
- However, direct inhibition of ENPP2 did not reverse the IL-1β-induced reduction in collagen contraction and instead reduced contraction when inhibited alone, indicating a complex role.
Interpretation and Conclusions
- IL-1β acts through multiple pathways to influence tendon cell function and gene expression, making it challenging to fully mitigate its effects by targeting individual signaling components.
- IRAK-4 inhibition can partially protect tendon cells from IL-1β effects but does not restore full function, suggesting redundancy or parallel pathways contribute to IL-1β’s impact.
- The partial rescue by PF-06650833 implies that IRAK-4 is an important but not exclusive mediator of IL-1β signaling in tendon cells.
- The incomplete gene expression rescue and persistent inflammation after IRAK-4 inhibition highlight the complexity of IL-1β signaling and its regulation of tendon cell biology.
- ENPP2’s role in tenocyte contraction and its regulation by IL-1β suggest it may be a downstream effector or marker but not a straightforward therapeutic target because its inhibition also reduces contraction.
- These findings underline the need for broader or multi-target therapeutic strategies to effectively counteract IL-1β-induced tendon damage and improve healing outcomes.
Cite This Article
APA
Beaumont RE, Flood C, Guest DJ.
(2025).
Inhibition of interleukin-1 receptor-associated kinase (IRAK)-4 provides partial rescue of interleukin-1 beta induced functional and gene expression changes in equine tenocytes.
Mol Biol Rep, 53(1), 54.
https://doi.org/10.1007/s11033-025-11219-2 Publication
Researcher Affiliations
- Centre for Vaccinology and Regenerative Medicine, Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK.
- Centre for Vaccinology and Regenerative Medicine, Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK.
- Centre for Vaccinology and Regenerative Medicine, Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK. djguest@rvc.ac.uk.
MeSH Terms
- Animals
- Horses
- Interleukin-1beta / metabolism
- Interleukin-1beta / pharmacology
- Tenocytes / metabolism
- Tenocytes / drug effects
- Interleukin-1 Receptor-Associated Kinases / antagonists & inhibitors
- Interleukin-1 Receptor-Associated Kinases / metabolism
- Interleukin-1 Receptor-Associated Kinases / genetics
- Signal Transduction / drug effects
- NF-kappa B / metabolism
- Sulfones / pharmacology
- Tendons / metabolism
- Tendons / cytology
- Nitriles / pharmacology
- Gene Expression Regulation / drug effects
- Cells, Cultured
Grant Funding
- S22-1151-1190 / Petplan Charitable Trust
- S22-1151-1190 / Petplan Charitable Trust
Conflict of Interest Statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval: The cells used in this study were collected and used with the approval of the Royal Veterinary College Clinical Research Ethical Review Board (URN 2020 2017-2).
References
This article includes 66 references
- Thomopoulos S, Parks WC, Rifkin DB, Derwin KA. Mechanisms of tendon injury and repair. J Orthop Res 33:832–839.
- Williams RB, Harkins LS, Wood JLN. Racehorse injuries, clinical problems and fatalities recorded on British racecourses from flat racing and National Hunt racing during 1996, 1997 and 1998. Equine Vet J 33:478–486.
- Kuo CK, Marturano JE, Tuan RS. Novel strategies in tendon and ligament tissue engineering: advanced biomaterials and regeneration motifs. BMC Sports Sci Med Rehabil 2:20.
- Hordé M, Fouchard J, Palacios LG, Laffray X, Blavet C, Béréziat V, Lagathu C, Gaut L, Duprez D, Havis E. Human adipose stromal cells differentiate towards a tendon phenotype with adapted visco-elastic properties in a 3D-culture system. Biol Open .
- Barsby T, Bavin EP, Guest DJ. Three-dimensional culture and transforming growth factor Beta3 synergistically promote tenogenic differentiation of equine embryo-derived stem cells. Tissue Eng Part A 20:2604–2613.
- Paterson YZ, Cribbs A, Espenel M, Smith EJ, Henson FMD, Guest DJ. Genome-wide transcriptome analysis reveals equine embryonic stem cell-derived tenocytes resemble fetal, not adult tenocytes. Stem Cell Res Ther 11:184.
- Beaumont RE, Smith EJ, David C, Paterson YZ, Faull E, Guest DJ. Equine adult, fetal and ESC-tenocytes have differential migratory, proliferative and gene expression responses to factors upregulated in the injured tendon. Cells Dev 181:204003.
- Smith EJ, Beaumont RE, McClellan A, Sze C, Palomino Lago E, Hazelgrove L, Dudhia J, Smith RKW, Guest DJ. Tumour necrosis factor alpha, Interleukin 1 beta and interferon gamma have detrimental effects on equine tenocytes that cannot be rescued by IL-1RA or mesenchymal stromal cell-derived factors. Cell Tissue Res 391:523–544.
- Beaumont RE, Smith EJ, Zhou L, Marr N, Thorpe CT, Guest DJ. Exogenous interleukin-1 beta stimulation regulates equine tenocyte function and gene expression in three-dimensional culture which can be rescued by pharmacological inhibition of interleukin 1 receptor, but not nuclear factor kappa B, signaling. Mol Cell Biochem .
- Smith EJ, Beaumont RE, Dudhia J, Guest DJ. Equine embryonic stem cell-derived tenocytes are insensitive to a combination of inflammatory cytokines and have distinct molecular responses compared to primary tenocytes. Stem Cell Rev Rep .
- McClellan A, Evans R, Sze C, Kan S, Paterson Y, Guest D. A novel mechanism for the protection of embryonic stem cell derived tenocytes from inflammatory cytokine Interleukin 1 beta. Sci Rep 9:2755.
- Morita W, Dakin SG, Snelling SJB, Carr AJ. Cytokines in tendon disease: a systematic review. Bone Joint Res 6:656–664.
- Koch DW, Berglund AK, Messenger KM, Gilbertie JM, Ellis IM, Schnabel LV. Interleukin-1β in tendon injury enhances reparative gene and protein expression in mesenchymal stem cells. Front Vet Sci 9:963759.
- Gotoh M, Hamada K, Yamakawa H, Tomonaga A, Inoue A, Fukuda H. Significance of granulation tissue in torn supraspinatus insertions: An immunohistochemical study with antibodies against interleukin‐1β, cathepsin D, and matrix metalloprotease‐1. J Orthop Res 15(1):33–39.
- Dakin SG, Martinez FO, Yapp C, Wells G, Oppermann U, Dean BJ, Smith RD, Wheway K, Watkins B, Roche L, Carr AJ. Inflammation activation and resolution in human tendon disease. Sci Transl Med 7:311ra173.
- Chan KM, Fu SC. Anti-inflammatory management for tendon injuries - friends or foes?. Sports Med Arthrosc Rehabil Ther Technol 1:23.
- Paterson Y, Rash N, Garvican E, Paillot R, Guest DJ. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro. Stem Cell Res Ther 5:90.
- Ranera B, Antczak D, Miller D, Doroshenkova T, Ryan A, McIlwraith CW, Barry F. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes. Equine Vet J 48:253–60.
- Hotham WE, Thompson C, Szu-Ting L, Henson FMD. The anti-inflammatory effects of equine bone marrow stem cell-derived extracellular vesicles on autologous chondrocytes. Vet Rec Open 8:e22.
- Koch DW, Froneberger A, Berglund A, Connard S, Souther A, Schnabel LV. IL-1β + TGF-β2 dual-licensed mesenchymal stem cells have reduced major histocompatibility class I expression and positively modulate tenocyte migration, metabolism, and gene expression. J Am Vet Med Assoc 262(S1):S61-s72.
- M’Cloud WRC, Guzmán KE, Panek CL, Colbath AC. Stem cells and platelet-rich plasma for the treatment of naturally occurring equine tendon and ligament injuries: a systematic review and meta-analysis. J Am Vet Med Assoc 262(S1):S50-s60.
- Soukup R, Gerner I, Mohr T, Gueltekin S, Grillari J, Jenner F. Mesenchymal stem cell conditioned medium modulates inflammation in tenocytes: complete conditioned medium has superior therapeutic efficacy than its extracellular vesicle fraction. Int J Mol Sci .
- Shin HM, Kim MH, Kim BH, Jung SH, Kim YS, Park HJ, Hong JT, Min KR, Kim Y. Inhibitory action of novel aromatic Diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett 571:50–54.
- Inayama M, Nishioka Y, Azuma M, Muto S, Aono Y, Makino H, Tani K, Uehara H, Izumi K, Itai A, Sone S. A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 173:1016–1022.
- Liu T, Zhang L, Joo D, Sun S-C. NF-κB signaling in inflammation. Signal Transduct Target Ther 2:17023.
- Pakjoo M, Ahmadi SE, Zahedi M, Jaafari N, Khademi R, Amini A, Safa M. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors. Cell Communication Signal 22:105.
- Lee J, Rhee MH, Kim E, Cho JY. BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm 2012:416036.
- Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, Gakidis MA, Rao A, Sekine T, Ikegami F, Yuan C, Yuan J. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ 11:123–130.
- Zou Z, Shang R, Zhou L, Du D, Yang Y, Xie Y, Li Z, Zhao M, Jiang F, Zhang L, Zhou P. The novel MyD88 inhibitor TJ-M2010-5 protects against hepatic ischemia-reperfusion injury by suppressing pyroptosis in mice. Transplantation 107:392–404.
- Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7:837–847.
- Liao X, Falcon N, Mohammed A, Paterson Y, Mayes A, Guest DJ, Saeed A. Synthesis and formulation of four-arm PolyDMAEA/siRNA polyplex for transient downregulation of collagen type III gene expression in TGF-β1 stimulated tenocyte culture. ACS Omega 5:1496–1505.
- Jo CH, Lim HJ, Yoon KS. Characterization of tendon-specific markers in various human tissues, tenocytes and mesenchymal stem cells. Tissue Eng Regen Med 16:151–159.
- Sanacora S, Urdinez J, Chang TP, Vancurova I. Anticancer drug bortezomib increases interleukin-8 expression in human monocytes. Biochem Biophys Res Commun 460:375–379.
- Laver T, Lee BM, Gogal RM. Bortezomib inhibits the proteasome, leading to cell death via apoptosis in feline injection site sarcoma cells in vitro. Am J Vet Res 83.
- Tong H, Zou C, Qin S, Meng J, Keller E, Zhang J, Lu Y. Prostate cancer tends to metastasize in the bone-mimicking microenvironment via activating NF-κB signaling. J Biomedical Res 32.
- Avci NG, Ebrahimzadeh-Pustchi S, Akay YM, Esquenazi Y, Tandon N, Zhu J-J, Akay M. NF-κB inhibitor with temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways. Sci Rep 10:13352.
- Yuan F, Chen J, Sun PP, Guan S, Xu J. Wedelolactone inhibits LPS-induced pro-inflammation via NF-kappaB pathway in RAW 264.7 cells. J Biomed Sci 20:84.
- Winkler A, Sun W, De S, Jiao A, Sharif MN, Symanowicz PT, Athale S, Shin JH, Wang J, Jacobson BA, Ramsey SJ, Dower K, Andreyeva T, Liu H, Hegen M, Homer BL, Brodfuehrer J, Tilley M, Gilbert Steven A, Danto SI, Beebe JJ, Barnes BJ, Pascual V, Lin L-L, Kilty I, Fleming M, Rao VR. The interleukin-1 receptor–associated kinase 4 inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheumatol 73:2206–2218.
- Salgado-Polo F, Borza R, Matsoukas MT, Marsais F, Jagerschmidt C, Waeckel L, Moolenaar WH, Ford P, Heckmann B, Perrakis A. Autotaxin facilitates selective LPA receptor signaling. Cell Chem Biol 30:69-84e14.
- Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14(4):417–419.
- Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4:1521.
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550.
- Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res 49:D545–D551.
- Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 36:2628–2629.
- Kaiser C, Knight A, Nordstrom D, Pettersson T, Fransson J, Florin-Robertsson E, Pilstrom B. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 32(2):295–299.
- Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232–241.
- Hosaka Y, Kirisawa R, Ueda H, Yamaguchi M, Takehana K. Differences in tumor necrosis factor (TNF)alpha and TNF receptor-1-mediated intracellular signaling factors in normal, inflamed and scar-formed horse tendons. J Vet Med Sci 67:985–991.
- Hosaka Y, Kirisawa R, Yamamoto E, Ueda H, Iwai H, Takehana K. Localization of cytokines in tendinocytes of the superficial digital flexor tendon in the horse. J Vet Med Sci 64:945–947.
- (U.S.) NLoM, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833 (2020–2022) A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, PF-06651600 (RITLECITINIB) AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH MODERATELY-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE. Identifier NCT04413617
- Palomino Lago E, Jelbert ER, Baird A, Lam PY, Guest DJ. Equine induced pluripotent stem cells are responsive to inflammatory cytokines before and after differentiation into musculoskeletal cell types. In Vitro Cellular & Developmental Biology 59:514–527.
- Guo R, Wang J, Tang W, Xiao D. Rnf144b alleviates the inflammatory responses and cardiac dysfunction in sepsis. ESC Heart Fail 10:2338–2344.
- Zhang Z, Zhang L, Wang B, Zhu X, Zhao L, Chu C, Guo Q, Wei R, Yin X, Zhang Y, Li X. RNF144B inhibits LPS-induced inflammatory responses via binding TBK1. J Leukoc Biol 106:1303–1311.
- Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity 47:15–31.
- Kyoreva M, Li Y, Hoosenally M, Hardman-Smart J, Morrison K, Tosi I, Tolaini M, Barinaga G, Stockinger B, Mrowietz U, Nestle FO, Smith CH, Barker JN, Di Meglio P. CYP1A1 enzymatic activity influences skin inflammation via regulation of the AHR pathway. J Invest Dermatol 141:1553-1563e3.
- Chen J-C, He M-Q. Inhibition of CYP1A1 expression enhances diabetic wound healing by modulating inflammation and oxidative stress in a rat model. Tissue Cell 90:102483.
- Recio C, Lucy D, Purvis GSD, Iveson P, Zeboudj L, Iqbal AJ, Lin D, O’Callaghan C, Davison L, Griesbach E, Russell AJ, Wynne GM, Dib L, Monaco C, Greaves DR. Activation of the immune-metabolic receptor GPR84 enhances inflammation and phagocytosis in macrophages. Front Immunol .
- Matsunaga N, Ikeda E, Kakimoto K, Watanabe M, Shindo N, Tsuruta A, Ikeyama H, Hamamura K, Higashi K, Yamashita T, Kondo H, Yoshida Y, Matsuda M, Ogino T, Tokushige K, Itcho K, Furuichi Y, Nakao T, Yasuda K, Doi A, Amamoto T, Aramaki H, Tsuda M, Inoue K, Ojida A, Koyanagi S, Ohdo S. Inhibition of G0/G1 switch 2 ameliorates renal inflammation in chronic kidney disease. EBioMedicine 13:262–273.
- Kendal AR, Layton T, Al-Mossawi H, Appleton L, Dakin S, Brown R, Loizou C, Rogers M, Sharp R, Carr A. Multi-omic single cell analysis resolves novel stromal cell populations in healthy and diseased human tendon. Sci Rep 10:13939.
- Bao Y, Tong C, Xiong X. CXCL3: a key player in tumor microenvironment and inflammatory diseases. Life Sci 348:122691.
- Buyukcelebi K, Chen X, Abdula F, Elkafas H, Duval AJ, Ozturk H, Seker-Polat F, Jin Q, Yin P, Feng Y, Bulun SE, Wei JJ, Yue F, Adli M. Engineered MED12 mutations drive leiomyoma-like transcriptional and metabolic programs by altering the 3D genome compartmentalization. Nat Commun 14:4057.
- Magkrioti C, Galaris A, Kanellopoulou P, Stylianaki E-A, Kaffe E, Aidinis V. Autotaxin and chronic inflammatory diseases. J Autoimmun 104:102327.
- Córdova-Casanova A, Cruz-Soca M, Chun J, Casar JC, Brandan E. Activation of the ATX/LPA/LPARs axis induces a fibrotic response in skeletal muscle. Matrix Biol 109:121–139.
- Ninou I, Magkrioti C, Aidinis V. Autotaxin in pathophysiology and pulmonary fibrosis. Front Med 5:180.
- Sakai N, Bain G, Furuichi K, Iwata Y, Nakamura M, Hara A, Kitajima S, Sagara A, Miyake T, Toyama T, Sato K, Nakagawa S, Shimizu M, Kaneko S, Wada T. The involvement of autotaxin in renal interstitial fibrosis through regulation of fibroblast functions and induction of vascular leakage. Sci Rep 9:7414.
- Lee DJ, Ho CH, Grinnell F. LPA-stimulated fibroblast contraction of floating collagen matrices does not require Rho kinase activity or Retraction of fibroblast extensions. Exp Cell Res 289:86–94.
- Szczesny SE, Corr DT. Tendon cell and tissue culture: perspectives and recommendations. J Orthop Res 2023;41:2093–2104.
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
